Hudson Portfolio Management LLC Purchases New Position in Thermo Fisher Scientific Inc. $TMO

Hudson Portfolio Management LLC acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 863 shares of the medical research company’s stock, valued at approximately $433,000.

Other large investors have also modified their holdings of the company. Brighton Jones LLC increased its stake in Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after buying an additional 988 shares during the period. Revolve Wealth Partners LLC increased its position in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after acquiring an additional 20 shares during the last quarter. Darwin Wealth Management LLC acquired a new position in shares of Thermo Fisher Scientific in the second quarter worth about $170,000. Raymond James Financial Inc. boosted its holdings in Thermo Fisher Scientific by 7.4% in the second quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock valued at $315,781,000 after purchasing an additional 53,542 shares during the last quarter. Finally, California State Teachers Retirement System grew its stake in Thermo Fisher Scientific by 0.4% during the 2nd quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock valued at $244,099,000 after purchasing an additional 2,262 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Activity at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 420 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the sale, the chief accounting officer directly owned 2,966 shares in the company, valued at approximately $1,734,546.46. This represents a 12.40% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $629.27, for a total value of $6,292,700.00. Following the completion of the sale, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $77,982,284.75. This trade represents a 7.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 73,768 shares of company stock valued at $44,122,820. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $608.33 on Thursday. The stock has a market capitalization of $224.93 billion, a PE ratio of 32.72, a price-to-earnings-growth ratio of 2.51 and a beta of 0.85. The business’s fifty day moving average price is $566.67 and its 200 day moving average price is $513.61. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $647.00.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. During the same period in the prior year, the company earned $4.28 earnings per share. The firm’s revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts forecast that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is presently 10.11%.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of recent analyst reports. Morgan Stanley upped their target price on Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a research report on Friday, July 24th. Piper Sandler lifted their price target on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a “neutral” rating in a research note on Monday, July 27th. KeyCorp reiterated an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Wells Fargo & Company decreased their price objective on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Finally, Royal Bank Of Canada upped their target price on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a research note on Friday, July 24th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $619.41.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.